Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
107 hedge funds and large institutions have $621M invested in Albireo Pharma Inc in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 23 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
16% more capital invested
Capital invested by funds: $533M → $621M (+$87.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 23
1% less funds holding
Funds holding: 108 → 107 (-1)
68% less call options, than puts
Call options by funds: $1.87M | Put options by funds: $5.87M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$20.3M |
| 3 |
BlackRock
New York
|
+$11.1M |
| 4 |
Goldman Sachs
New York
|
+$6.33M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$6.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$20M |
| 2 |
O
OrbiMed
New York
|
-$11M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.27M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.79M |
| 5 |
AG
Artal Group
Luxembourg
|
-$5.51M |
ALBO Hedge Fund Activity: Q4 2020 in Review
107 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q4 2020, worth a combined $621M — up 16% from $533M a quarter earlier.
Fund positioning in ALBO was balanced in Q4 2020: 23 funds opened new positions, 23 closed out, 44 added to existing stakes and 30 trimmed.
The largest buyer was Vanguard Group, adding an estimated $21.8M. The largest seller was Cowen and Company, exiting entirely with an estimated $20M sold.
- 107 institutional investors held Albireo Pharma Inc (ALBO) as of Q4 2020, down from 108 in Q3 2020.
- Funds reported $621M of Albireo Pharma Inc stock for Q4 2020, up 16% quarter-over-quarter.
- 23 funds opened new Albireo Pharma Inc positions in Q4 2020 and 23 closed out, a net change of 0 holders.
- The largest Albireo Pharma Inc buyer in Q4 2020 was Vanguard Group, an estimated $21.8M added.
- The largest Albireo Pharma Inc seller in Q4 2020 was Cowen and Company, an estimated $20M sold.
Based on aggregated 13F filings for Q4 2020.